Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Study of Donepezil SR 23 mg vs IR 10 mg in Severe Alzheimer's Disease (Japan)
jRCT2080221358Phase 2
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of donepezil in Alzheimer's disease (AD) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Primary safety assessment of E2020 SR 23 mg.
02
Drugs
donepezil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080221358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221358.